At the same time, through the analysis of a large number of clinical research data, the researchers found that serum exosome HMGA2 has unique advantages in predicting the metastatic potential of nasopharyngeal carcinoma, and it can be used as an effective non-invasive biomarker to detect the metastatic potential of nasopharyngeal carcinoma patients and provide a reference value for their prognosis evaluation. This evidence concerns the gene HMGA2 and nasopharyngeal carcinoma.